Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series

Abstract

Background: Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) that is approved for the treatment of type 2 diabetes mellitus (T2D). Despite its similarities to GLP-1 RA, there is a lack of data on how to switch between GLP-1 RA and GIP/GLP-1 RA. Objectives: The objective of this study is to evaluate the efficacy and safety of switching from GLP-1 RA to tirzepatide in patients with T2D and provide guidance for switching between the two classes. Methods: This was a retrospective case series of patients with T2D who met protocol criteria for switching between the two classes. Hemoglobin A1C (A1C) and weight data were evaluated at 3 and 6 months. Results: A total of 10 patients were included. Mean change from baseline in A1C was −0.7 ± 0.9% at 3 months (N = 8) compared to −1.4 ± 0.7% at 6 months (N = 4). Percentage of patients who achieved their goal A1C was 25% (2/8) at 3 months post switch compared to 50% (2/4) at 6 months. Mean change from baseline in weight was −3.6 ± 2.3 kg at 3 months and −6 ± 3.4 kg at 6 months. Percentage of patients who achieved weight loss from baseline of ≥10% was 0 at 3 months versus 33.3% (1/3) at 6 months. Few adverse events were reported after switching. Conclusion: Switching can be considered for patients with T2D that require further A1C and weight reduction to reach their target goals despite being on GLP-1 RA.

Keywords

tirzepatide type 2 diabetes switch glucagon-like petide-1 receptor agonist

Get full access to this article

View all access options for this article.

References

U.S. Food and Drug Administration. FDA approves novel, dual-targeted treatment for type 2 diabetes. Published May 13, 2022. Accessed September 30, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes

Fisman

Tenenbaum

. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225.

Mathiesen

Bagger

Bergmann

, et al. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion—a review. Int J Mol Sci. 2019;20(17):4092.

NEJM Journal Watch. Tirzepatide, a potential new agent for type 2 diabetes. Published July 8, 2021. Accessed September 30, 2023. https://www.jwatch.org/na53795/2021/07/08/tirzepatide-potential-new-agent-type-2-diabetes

Mounjaro. Prescribing information. Revised 2023. Accessed September 30, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866Orig1s002s006lbl.pdf

Ozempic. Prescribing information. Revised 2023. Accessed September 30, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf

Trulicity. Prescribing information. Revised 2022. Accessed September 30, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s051lbl.pdf

ElSayed

Aleppo

Aroda

, et al. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care. 2023;46(suppl 1):S140-S157.

ElSayed

Aleppo

Aroda

, et al. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes—2023. Diabetes Care. 2023;46 (suppl 1):S128-S139.

10.

Samson

Vellanki

Blonde

, et al. American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm—2023 update. Endocr Pract. 2023;29(5):305-340.

11.

Williamson

Bray

Ryan

. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss? Obesity (Silver Spring). 2015;23(12):2319-2320.

12.

Jain

Ali

Gorgojo Martínez

, et al. Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance. Int J Clin Pract. 2021;75(2):e13731.

13.

Frias

Davies

Rosenstock

, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.

14.

Mishra

Raj

Elshimy

, et al. Adverse events related to tirzepatide. J Endocr Soc. 2023;7(4):bvad016.

15.

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.

16.

eMedNY. Medicaid pharmacy list of reimbursable drugs. Accessed September 30, 2023. https://www.emedny.org/info/formfile.aspx

17.

Mounjaro. Coverage and savings support. Accessed September 30, 2023. https://www.mounjaro.com/hcp/savings-resources.

18.

ClinicalTrials.gov. A study of tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type 2 diabetes (SURPASS-CVOT). Accessed September 30, 2023. https://www.clinicaltrials.gov/study/NCT04255433?term=tirzepatide&page=3&rank=28.

19.

ClinicalTrials.gov. A study of tirzepatide (LY3298176) in adult participants with type 2 diabetes switching from dulaglutide (SURPASS-SWITCH) (SURPASS-SWITCH). Accessed September 30, 2023. https://www.clinicaltrials.gov/study/NCT05564039?term=tirzepatide&page=4&rank=34.

20.

ClinicalTrials.gov. A study of tirzepatide (LY3298176) in adults with type 2 diabetes switching from a GLP-1 RA (SURPASS-SWITCH-2). Accessed September 30, 2023. https://clinicaltrials.gov/study/NCT05706506?term=tirzepatide&rank=9.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB